Table 3.
Change from baseline fasting plasma glucose and cardiometabolic risk factors in SURPASS programme and SURMOUNT-1 study
| Trial | Treatment arm | Change from baseline | % Change from baseline | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| WC (cm) | FSG* (mg/dL) | SBP (mmHg) | DBP (mmHg) | Total cholesterol | LDL-C (mg/dL) | Triglycerides | HDL-C (mg/dL) | ALT | AST | ||
| SURPASS-1 | Tirzepatide 5 mg | –5.7 | –43.6 | –4.7† | –2.9† | –5.47 | –6.66† | –18.5 | 4.8 | –29.1 | –11.6 |
| Tirzepatide 10 mg | –6.9 | –45.9 | –5.2 | –3.1† | –6.34 | –7.58† | –18.2 | 3.2 | –25.7 | –9.5† | |
| Tirzepatide 15 mg | –7.2 | –49.3 | –4.7† | –3.4† | –8.43 | –12.43 | –21.0 | 7.5 | –32.9 | –13.9 | |
| Placebo | –2.0 | 12.9 | –2.0 | –1.4 | –0.76 | –1.64 | 4.7 | –3.8 | –10.2 | –2.6 | |
| SURPASS-2 | Tirzepatide 5 mg | –6.9 | –56.0 | –4.8 | –1.9 | –5.49† | –7.68† | –19.0 | 6.8 | –22.4† | –8.7† |
| Tirzepatide 10 mg | –9.6 | –61.6 | –5.3 | –2.5 | –5.96† | –5.59† | –24.1 | 7.9 | –29.2 | –13.7 | |
| Tirzepatide 15 mg | –9.9 | –63.4 | –6.5 | –2.9 | –6.26† | –5.15† | –24.8 | 7.1 | –30.0 | –14.1 | |
| Semaglutide 1 mg | –5.6 | –48.6 | –3.6 | –1.0 | –4.78 | –6.39 | –11.5 | 4.4 | –21.6 | –9.2 | |
| SURPASS-3 | Tirzepatide 5 mg | –7.1 | –48.2 | –4.9 | –2.0 | –4.25† | –6.01† | –15.4† | 5.5 | –22.3 | –11.4 |
| Tirzepatide 10 mg | –9.4 | –54.8† | –6.6 | –2.5 | –5.81† | –5.70† | –26.7 | 10.2 | –27.4 | –12.8 | |
| Tirzepatide 15 mg | –10.9 | –59.2† | –5.5 | –1.9 | –5.69† | –6.55† | –25.2 | 10.2 | –30.7 | –16.4 | |
| Insulin degludec | 0.7 | –55.7 | 0.5 | 0.4 | –2.92 | –2.71 | –12.2 | 1.0 | –17 | –5.8 | |
| SURPASS-4 | Tirzepatide 5 mg | –8.0 | –50.4† | –2.8 | –1.0 | –5.1 | –6.8 | –16.3 | 6.7 | NR | NR |
| Tirzepatide 10 mg | –10.1 | –54.9† | –3.7 | –0.8 | –5.5 | –8.3 | –20.1 | 9.7 | NR | NR | |
| Tirzepatide 15 mg | –8.9 | –59.3 | –4.8 | –1.0 | –5.6 | –7.9 | –22.5 | 10.8 | NR | NR | |
| Insulin lantus | 2.3 | –51.4 | 1.3 | 0.7 | 0 | 1.4 | –6.4 | 2.9 | NR | NR | |
| SURPASS-5 | Tirzepatide 5 mg | –3.8 | –61.4 | –6.1 | –2.0 | –8.8 | –8.9 | –15.2 | 2.1† | –19.4 | –4.1† |
| Tirzepatide 10 mg | –7.4 | –67.9 | –8.3 | –3.3 | –10.3 | –12.8 | –19.3 | 1.8† | –23.3 | –8.6 | |
| Tirzepatide 15 mg | –8.9 | –67.7 | –12.6 | –4.5 | –12.9 | –15.5 | –24.9 | 0.9† | –28.3 | –14.1 | |
| Placebo | 1.0 | –38.9 | –1.7 | –2.1 | –0.4 | 2.8 | –6.8 | 1.7 | –7.5 | 0.0 | |
| SURPASS J-mono | Tirzepatide 5 mg | –5.4 | –57.9 | –6.5 | –3.2 | –10.0 | –12.0 | –27.1 | 3.8 | –26.2 | –14.0 |
| Tirzepatide 10 mg | –6.8 | –64.4 | –8.8 | –4.0 | –11.6 | –12.8 | –32.8 | 5.4 | –30.7 | –14.9 | |
| Tirzepatide 15 mg | –9.8 | –67.6 | –11.0 | –5.6 | –15.4 | –19.3 | –37.7 | 5.9 | –32.4 | –17.9 | |
| Dulaglutide 0.75 mg | 0.4 | –31.9 | –1.4 | 0.1 | –3.8 | –4.8 | –8.2 | 0 | –0.9 | 2.2 | |
| SURPASS J-combo | Tirzepatide 5 mg | –3.3 | –58.6 | –5.1 | –2.7 | –11.1 | –13.6 | –21.9 | 0.9 | –14.7 | –4.7 |
| Tirzepatide 10 mg | –7.2 | –71.2 | –10.2 | –3.6 | –13.4 | –15.1 | –31.1 | 2.4 | –23.9 | –13.8 | |
| Tirzepatide 15 mg | –9.0 | –74.4 | –8.7 | –3.4 | –14.6 | –18.0 | –37.4 | 5.1 | –28.9 | –12.2 | |
| SURMOUNT-1 | Tirzepatide 5 mg | –14.6 | NA | –7.0 | –5.2 | –4.9 | –5.3 | –24.3 | 7.0 | –25.7 | –11.4 |
| Tirzepatide 10 mg | –19.4 | NA | –8.2 | –5.5 | –5.6 | –6.6 | –27.0 | 8.6 | –28.1 | –12.1 | |
| Tirzepatide 15 mg | –19.9 | NA | –7.6 | –4.6 | –7.4 | –8.6 | –31.4 | 8.2 | –30.3 | –14.2 | |
| Placebo | –3.4 | NA | –1.2 | –1.0 | –1.1 | –0.9 | –6.3 | 0.2 | –12.8 | –6.6 | |
*Efficacy estimand; †No significant difference from comparator.
WC, waist circumference; FSG, fasting serum glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; ALT, alanine transaminase; AST, aspartate transaminase; NR, not reported; NA, not applicable.